Specifically, in hepatocellular carcinoma (HCC) patients with high ITGA2 expression, a first-line treatment strategy combining lenvatinib with an ITGA2 inhibitor may potentially prevent or delay the acquisition of drug resistance. This evidence concerns the gene ITGA2 and hepatocellular carcinoma.